Understanding how a specific enzyme contributes to Celiac disease
Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
This study is looking at how a protein called transglutaminase 2 (TG2) works with gluten in people with Celiac disease, to help understand the immune response and find new ways to treat the condition beyond just avoiding gluten.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10873135 on NIH RePORTER |
What this research studies
This research investigates the role of transglutaminase 2 (TG2) in Celiac disease, a condition triggered by gluten that affects the small intestine. The study aims to identify how TG2 interacts with gluten peptides and contributes to the immune response that leads to the disease. By conducting both laboratory and animal studies, the researchers will explore the biochemical mechanisms behind TG2's activity and its involvement in forming autoantibodies. This research could provide insights into potential therapeutic targets for Celiac disease beyond dietary restrictions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Celiac disease who are experiencing symptoms despite adhering to a gluten-free diet.
Not a fit: Patients who do not have Celiac disease or those who have already developed complications from long-term gluten exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with Celiac disease, improving their quality of life.
How similar studies have performed: Previous research has shown promising results in understanding the immune mechanisms of Celiac disease, making this approach a continuation of established findings.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Khosla, Chaitan — Stanford University
- Study coordinator: Khosla, Chaitan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.